scholarly journals The relative change in regulatory T cells / T helper lymphocytes ratio as parameter for prediction of therapy efficacy in metastatic colorectal cancer patients

Oncotarget ◽  
2017 ◽  
Vol 8 (65) ◽  
pp. 109079-109093 ◽  
Author(s):  
Tong Xu ◽  
Jiezhen Lu ◽  
Hanxiang An
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
Regulatory T Cells ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
T Helper ◽  
T Helper Lymphocytes ◽  
Therapy Efficacy ◽  
Colorectal Cancer Patients ◽  
Relative Change

CTLs/regulatory T-cells ratio as a prediction marker of chemotherapy in metastatic colorectal cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e14684-e14684
Author(s):  
Teruo Sasatomi ◽  
Takafumi Oochi ◽  
Yutaka Ogata ◽  
Yoshito Akagi ◽  
Kazuo Shirouzu
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
Regulatory T Cells ◽  
Metastatic Colorectal Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Metastatic Lesion ◽  
The Other ◽  
Before And After ◽  
Colorectal Cancer Patients

e14684 Background: Many multiple anti cancer drugs regimens have been established for metastaticcolorectal cancer recently. We investigated cellular immunoreaction of these patients to their cancer. Methods: 32 metastatic colorectal cancer patients have been started chemotherapies. Their PBMCs were harvested and investigated their character by Fac scan with fluorescent labeled antibodies (CD3,CD8, CD4, CD25, Foxp3) at before and after chemotherapy. Results: After chemotherapy, both CTLs(CD3, CD8 positive) and regulatory T cells (CD4, CD25, Foxp3 positive) were decreased in number among all patients. On the other hand, CTL/T reg ratio were significantly increased among tumor marker decreased patients and significantly decreased among tumor marker increased or stable patients. CEA levels among 85.7% of increased CTL/T reg ratio patients became to decrease less thanhalf. CEA levels among 66.7% of decreased CTL/T reg ratio patients became to increase or to be stable, if their regimens have not been changed. The Reactive Rate of chemotherapy of CTL/T reg ratio increased patients was significantly higher than that of ratio decreased or stable patients. (P=0.021) The Disease Control Rate of chemotherapy of CTL/T reg ratio increased patients was higher than that of ratio decreased patients. Both resectability rate of liver metastatic lesion and early tumor shrinkage rate were higher at the CTL/T reg ratio increased patients group than at the other patients group. Conclusions: We found that the CTL/T reg ratios of PBMC in metastatic colorectal cancer patients were useful for prediction of the effect of chemotherapy.

Impact of antiangiogenic treatments on exhausted PD-1+ T lymphocytes in colorectal cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e22121-e22121 ◽  
Author(s):  
Simon Pernot ◽  
Magali Terme ◽  
Elie Marcheteau ◽  
Thibault Voron ◽  
Orianne Colussi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
T Lymphocytes ◽  
Regulatory T Cells ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Kinase Inhibitors ◽  
Anti Vegf ◽  
Colorectal Cancer Patients

e22121 Background: Tumors develop immunosuppressive mechanisms to escape the immune system. Among these mechanisms, T lymphocytes can express inhibitory molecules such as Program Death-1 (PD-1) protein which impair their activation and their effector functions. Multi-target anti-angiogenic tyrosine kinase inhibitors (TKI) that are routinely used as first- or second-line treatment of cancer patients, have been shown to modulate immunosuppressive mechanisms especially regulatory T cells. However, the role of specific VEGF/VEGFR blockade on PD-1 expression by T lymphocytes has not been studied. Methods: PD-1 expression on T lymphocytes has been analyzed by flow cytometry in a mouse model of colorectal cancer (CT26) treated by anti-angiogenic molecules targeting the VEGF-A/VEGFR axis and in the peripheral blood of metastatic colorectal cancer patients. Results: Sunitinib that directly targets VEGFR, PDGFR, c-kit, but also anti-VEGF-A antibody (the mouse orthologue of bevacizumab) decrease PD-1 expression on T lymphocytes infiltrating the tumors. Interestingly, anti-angiogenic treatments decrease the percentage of lymphocytes expressing not only PD-1 but also Tim-3 suggesting that the most exhausted T cells are targeted by anti-angiogenic treatments. Administration of masitinib, a TKI acting on KIT, PDGFR and FAK but not on the VEGF/VEGF-R pathway, was not able to modulate PD-1 expression on T cells. Finally, anti-VEGF-A treatment (bevacizumab) associated with chemotherapy decreases the proportion of PD-1+ CD4+T cells in the peripheral blood of metastatic colorectal cancer patients. Conclusions: These results show that anti-angiogenic treatments targeting VEGFA/VEGFR decrease PD-1-expressing T lymphocytes in colorectal cancer. These results suggest that VEGF-A could be involved in PD-1 expression and maybe in the induction of T lymphocyte exhaustion in colorectal cancer. We and others have shown that anti-angiogenic molecules could modulate other immunosuppressive populations such as regulatory T cells and myeloid suppressive cells, anti-angiogenic molecules might be efficiently associated with immunotherapeutic strategies in colorectal cancer.

scholarly journals Distribution of Regulatory T-Cells and Other Phenotypes of T-Cells in Tumors and Regional Lymph Nodes of Colorectal Cancer Patients

In Vivo ◽  
2020 ◽  
Vol 34 (2) ◽  
pp. 849-856
Author(s):  
KEISUKE KAZAMA ◽  
JUNYA OTAKE ◽  
TETSUTA SATOYOSHI ◽  
MANABU SHIOZAWA ◽  
NOBUHIRO SUGANO ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
Regulatory T Cells ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Regional Lymph Nodes ◽  
Colorectal Cancer Patients

Inclusion of BLIMP-1+ effector regulatory T cells improves the Immunoscore in a cohort of New Zealand colorectal cancer patients: a pilot study

2017 ◽  
Vol 66 (4) ◽  
pp. 515-522 ◽  
Author(s):  
Kirsten A. Ward-Hartstonge ◽  
John L. McCall ◽  
Timothy R. McCulloch ◽  
Ann-Kristin Kamps ◽  
Adam Girardin ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
New Zealand ◽  
Pilot Study ◽  
Regulatory T Cells ◽  
Cancer Patients ◽  
Colorectal Cancer Patients

scholarly journals Inflammatory and regulatory T cells contribute to a unique immune microenvironment in tumor tissue of colorectal cancer patients

2012 ◽  
Vol 132 (8) ◽  
pp. 1842-1850 ◽  
Author(s):  
Adam Girardin ◽  
John McCall ◽  
Michael A. Black ◽  
Francesca Edwards ◽  
Vicky Phillips ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
Regulatory T Cells ◽  
Cancer Patients ◽  
Tumor Tissue ◽  
Immune Microenvironment ◽  
Colorectal Cancer Patients

Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner

2007 ◽  
Vol 57 (6) ◽  
pp. 813-821 ◽  
Author(s):  
Sheraz Yaqub ◽  
Karen Henjum ◽  
Milada Mahic ◽  
Frode L. Jahnsen ◽  
Einar M. Aandahl ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
Regulatory T Cells ◽  
Cancer Patients ◽  
Dependent Manner ◽  
Immune Activity ◽  
Cox 2 ◽  
Colorectal Cancer Patients

Immunological effects as a biomarker of chemotherapy in metastatic colorectal cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14077-e14077
Author(s):  
Teruo Sasatomi ◽  
Yutaka Ogata ◽  
Hideaki Yamana ◽  
Yoshito Akagi ◽  
Kazuo Shirouzu
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
Metastatic Colorectal Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
The Other ◽  
Anti Cancer ◽  
Before And After ◽  
Immunological Effects ◽  
Colorectal Cancer Patients

e14077 Background: Many multiple anti cancer drugs regimens have been established for metastatic colorectal cancer recently. We investigated cellular immunoreaction of these patients to their cancer. Methods: 26 metastatic colorectal cancer patients have been started chemotherapies. Their PBMC were harvested and investigated their character by Fac scan with fluorescent labeled antibodies (CD3, CD8, CD4, CD25, Foxp3) at before and after chemotherapy. Results: After chemotherapy, both CTLs (CD3, CD8 positive) and regulatory T cells (CD4, CD25, Foxp3 positive) were decreased in number among all patients. On the other hand, CTL/T reg ratio were significantly increased among tumor marker decreased patients and significantly decreased among tumor marker increased or stable patients. CEA levels among 85.7% of increased CTL/T reg ratio patients became to decrease less than half. CEA levels among 66.7% of decreased CTL/T reg ratio patients became to increase or to be stable, if their regimens have not been changed. The Reactive Rate of chemotherapy of CTL/T reg ratio increased patients was significantly higher than that of ratio decreased patients. (p=0.021) The Disease Control Rate of chemotherapy of CTL/T reg ratio increased patients was higher than that of ratio decreased patients. Conclusions: We found that the CTL/T reg ratio of PBMC in metastatic colorectal cancer patients were useful for prediction of the effect of chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document